Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

illuma-HMO

More Like This

PR Newswire associated0

Wyeth Becomes the First Multinational Company to Launch an HMO Growing-Up Infant Formula in China

PR Newswire associated0

New Illuma Growing-up Infant Formula Now Available throughout China

PR Newswire associated0

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

PR Newswire associated0

dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition

PR Newswire associated0

Yili Launches Pro-Kido Infant Formula in Hong Kong Amid Global Expansion Efforts

Philip Morris International Launches New IQOS ILUMA i in Japan to Accelerate the Achievement of a Smoke-Free Future

Philip Morris International Submits Applications to Commercialize IQOS ILUMA Tobacco Heating System to U.S. Food and Drug Administration

Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)

Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut